Our CEO Joe Wiley is a doctor by training with a deep interest in rare and debilitating diseases, who felt compelled to do something to transform the lives of patients living with these conditions. Joe gathered a team of experts, all with two things in common – experience in rare diseases and a passion to provide much needed treatment options for these patients, and that’s where Amryt Pharma started in 2015. Since then, we have acquired 3 companies, we now commercialise 3 products and have helped thousands of patients with rare, debilitating diseases, and we’re not stopping there…for more information on what’s next see Our Pipeline.
We transform the lives of people affected by rare, debilitating conditions by providing innovative medicines that bring hope to those in greatest need.
Amryt is a biopharmaceutical company dedicated to developing and delivering innovative new treatments to help improve the lives of patients with rare and debilitating diseases. Amryt comprises a profitable and growing commercial business with a significant development pipeline.
A core belief at Amryt Pharma is that we operate on a foundation of responsibility, integrity and ethical practice. We aim to forge partnerships and collaborations that work for all. By listening to our stakeholders and most importantly our patients, we create a clear path for our transformative medicines to reach those that need them.
Amryt is dedicated purely to rare diseases. Our leadership team all have strong heritage in rare diseases, and it is through bringing them together that we are able to commit completely to delivering medicines that are truly transformative for people with rare, debilitating illnesses.
Our exceptional team offers a wealth of experience in identifying, commercialising and delivering new treatments across global markets. Our ability to navigate diverse regulatory and reimbursement environments, combining a ‘think global, act local approach’, positions us optimally to deliver our goals and get our life changing medicines to all those who need them.
Click here to see our leadership team.